Clinical Trial Update: Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating FE 203799 in adults with lymphomas has been withdrawn. The study examined safety, tolerability, and PK/PD in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• FE 203799

Snippet

Sponsor: GlyPharma Therapeutics | Conditions: Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Hodgkin's, Adult | Phase 1, Phase 2 | Status: WITHDRAWN